rank,account_name,fit,urgency,total,fit_reason,urgency_reason,urgency_source,trigger_summary,best_fit_trial_title,best_fit_trial_status,best_fit_trial_phase,best_fit_trial_url,best_urgency_trial_title,best_urgency_trial_status,best_urgency_trial_phase,best_urgency_trial_url,sec_matched_total,patent_matched_total,job_target_roles
,AstraZeneca,5.0,3.0,21.0,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,"trial_candidate: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subje | trial_candidate: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Posit | trial_candidate: Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors","A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma",RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT05850234,"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.",RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06542250,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,SecuraBio,5.0,3.0,19.0,CAR-T trial,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy,Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy,ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05044039,Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy,ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05044039,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,Legend Biotech USA Inc,5.0,3.0,19.0,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer,DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05680922,DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05680922,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,Invectys,5.0,3.0,19.0,CAR-T trial,"ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_collaborator: A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanc,A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT05672459,A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT05672459,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,"Chongqing Precision Biotech Co., Ltd",5.0,3.0,19.0,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE | trial_collaborator: CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases | trial_candidate: A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer,Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07318259,Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07318259,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,"Hebei Senlang Biotechnology Inc., Ltd.",5.0,3.0,19.0,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_collaborator: Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL,Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06880913,Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06880913,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,Tessa Therapeutics,5.0,3.0,19.0,CAR-T trial,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma,Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma,ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT04526834,Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma,ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT04526834,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,Miltenyi Biomedicine GmbH,5.0,3.0,19.0,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_candidate: MB-dNPM1-TCR.1 in Relapsed/Refractory AML | trial_candidate: Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell N | trial_candidate: MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM),"The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies",NOT_YET_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT07020260,MB-dNPM1-TCR.1 in Relapsed/Refractory AML,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06424340,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,Incyte Corporation,5.0,3.0,19.0,CAR-T trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | trial_collaborator: Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy,Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05757219,A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07195916,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,Bristol-Myers Squibb,5.0,3.0,19.0,CAR-T trial,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | trial_collaborator: French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T),French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T),RECRUITING,,https://clinicaltrials.gov/study/NCT04328298,Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma,ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05621096,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,"Shanghai Ming Ju Biotechnology Co., Ltd.",5.0,3.0,19.0,CAR-T trial,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_candidate: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma | trial_candidate: CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma | trial_collaborator: MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors,CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma,ACTIVE_NOT_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT06149169,CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma,ACTIVE_NOT_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT06149169,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,Bellicum Pharmaceuticals,5.0,3.0,19.0,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_collaborator: Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC,Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06096038,Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT06096038,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,UTC Therapeutics Inc.,5.0,3.0,19.0,CAR-T trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_collaborator: CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma,CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT05948033,CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT05948033,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,Pfizer,4.0,3.0,19.0,molecule match: elranatamab,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_candidate: A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With D | trial_candidate: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (M | trial_candidate: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myelo","A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy",RECRUITING,PHASE3,https://clinicaltrials.gov/study/NCT05623020,A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05675449,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,Imugene Limited,4.0,3.0,17.0,molecule match: blinatumomab,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refra | trial_candidate: A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Soli,A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS),ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06063317,Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL),RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT03666000,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,Celgene Corporation,4.0,3.0,17.0,molecule match: talquetamab,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_collaborator: A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relap | trial_collaborator: Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma",Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06348108,Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06348108,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,Amgen,4.0,3.0,17.0,molecule match: blinatumomab,RECRUITING in high urgency phase (PHASE2),clinicaltrials,"trial_collaborator: Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab | trial_candidate: Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Ca | trial_candidate: Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer","Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT03263572,Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT07061080,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,Takeda,4.0,3.0,17.0,molecule match: blinatumomab,RECRUITING in high urgency phase (PHASE2),clinicaltrials,"trial_candidate: A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myel | trial_collaborator: Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positi","Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT03263572,"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT03263572,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,Regeneron Pharmaceuticals,4.0,3.0,17.0,molecule match: odronextamab,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,"trial_candidate: A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who  | trial_candidate: Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | trial_candidate: A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in A",A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies,ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT02651662,A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA),RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT05092347,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,Janssen Pharmaceuticals,4.0,3.0,17.0,molecule match: teclistamab,RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_collaborator: Teclistamab-Daratumumab in AL Amyloidosis,Teclistamab-Daratumumab in AL Amyloidosis,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT07110844,Teclistamab-Daratumumab in AL Amyloidosis,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT07110844,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,Genmab,4.0,3.0,17.0,molecule match: epcoritamab,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_candidate: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | trial_candidate: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and,Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma,ACTIVE_NOT_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05660967,Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma,ACTIVE_NOT_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05660967,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,Eli Lilly and Company,4.0,3.0,17.0,molecule match: mosunetuzumab,RECRUITING in high urgency phase (PHASE2),clinicaltrials,"trial_collaborator: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and | trial_collaborator: Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROM","Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial",RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT06948786,"Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial",RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT06948786,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,"Janssen Research & Development, LLC",4.0,3.0,17.0,molecule match: teclistamab,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE2),clinicaltrials,"trial_candidate: A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | trial_candidate: Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | trial_candidate: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed ",A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT04557098,A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT04557098,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,Johnson & Johnson,4.0,3.0,17.0,molecule match: teclistamab,RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_collaborator: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma,Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05972135,Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT05972135,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,Cullinan Therapeutics Inc.,4.0,3.0,17.0,T cell engager / CD3 / bispecific trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_candidate: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | trial_candidate: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupu | trial_candidate: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Dis","A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06613360,CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05143996,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,"Genentech, Inc.",4.0,3.0,17.0,molecule match: mosunetuzumab,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Agg | trial_collaborator: Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High,Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma,ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05464329,Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma,ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05464329,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,Pharmacyclics LLC.,4.0,3.0,17.0,molecule match: blinatumomab,RECRUITING in high urgency phase (PHASE2),clinicaltrials,trial_collaborator: Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia,Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT02997761,Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia,RECRUITING,PHASE2,https://clinicaltrials.gov/study/NCT02997761,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,Janssen Pharmaceutical K.K.,4.0,3.0,17.0,molecule match: teclistamab,"ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_candidate: A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma,A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT04696809,A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT04696809,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,Bioray Laboratories,5.0,2.0,16.0,CAR-T trial,NOT_YET_RECRUITING,clinicaltrials,trial_collaborator: Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.,Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.,NOT_YET_RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT06485232,Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.,NOT_YET_RECRUITING,EARLY_PHASE1,https://clinicaltrials.gov/study/NCT06485232,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,Gilead Sciences,5.0,2.0,16.0,CAR-T trial,RECRUITING,clinicaltrials,trial_collaborator: French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T),French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T),RECRUITING,,https://clinicaltrials.gov/study/NCT04328298,French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T),RECRUITING,,https://clinicaltrials.gov/study/NCT04328298,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,Novartis,5.0,2.0,16.0,CAR-T trial,RECRUITING,clinicaltrials,trial_collaborator: French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T),French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T),RECRUITING,,https://clinicaltrials.gov/study/NCT04328298,French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T),RECRUITING,,https://clinicaltrials.gov/study/NCT04328298,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,"Corregene Biotechnology Co., Ltd",3.0,3.0,15.0,cell therapy / TCR trial,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors | trial_candidate: CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers,KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06767046,KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06767046,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,"Shanghai Ruiliyuan Biotechnology Co., Ltd.",3.0,3.0,15.0,cell therapy / TCR trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors,HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06515314,HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06515314,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,Neowise Biotechnology,3.0,3.0,15.0,cell therapy / TCR trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors | trial_collaborator: T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Adva | trial_collaborator: T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Adva,TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07266298,TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT07266298,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,SCG Cell Therapy Pte. Ltd.,3.0,3.0,15.0,cell therapy / TCR trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,trial_candidate: A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma | trial_candidate: A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | trial_candidate: Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma,A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06617000,A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT05417932,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,"Affini-T Therapeutics, Inc.",3.0,3.0,15.0,cell therapy / TCR trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Recepto | trial_candidate: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Meta,Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06043713,Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06043713,0,0,"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
,Lion TCR Pte. Ltd.,3.0,3.0,15.0,cell therapy / TCR trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_candidate: Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma | trial_candidate: Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | trial_candidate: Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV),Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06961617,Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma,RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06961617,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,"Iovance Biotherapeutics, Inc.",3.0,3.0,15.0,cell therapy / TCR trial,"RECRUITING in high urgency phase (PHASE1,PHASE2)",clinicaltrials,"trial_collaborator: E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | trial_collaborator: E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | trial_collaborator: KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer",E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT05639972,E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers,RECRUITING,"PHASE1,PHASE2",https://clinicaltrials.gov/study/NCT05639972,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,"Guangzhou FineImmune Biotechnology Co., LTD.",3.0,3.0,15.0,cell therapy / TCR trial,RECRUITING in high urgency phase (PHASE1),clinicaltrials,"trial_candidate: An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors | trial_candidate: Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors","An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06942143,"An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors",RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT06942143,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
,Celldex Therapeutics,3.0,3.0,15.0,cell therapy / TCR trial,ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1),clinicaltrials,trial_collaborator: Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T),Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T),ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05349890,Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T),ACTIVE_NOT_RECRUITING,PHASE1,https://clinicaltrials.gov/study/NCT05349890,0,0,"[""Clinical Scientist / Early Clinical Development Lead (Phase 1)"", ""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development""]"
